Globally, ovarian cancer (OC) is the eighth most common malignant tumour in women. Unfortunately, its symptoms—especially at the early stages—are vague and nonspecific, and, thus, most patients are diagnosed at the advanced stages of the disease (stage III and IV) when treatment is not curative. The currently available approved biomarkers are not sufficient for effective screening, prognosis, or monitoring of OC. Liquid biopsy tests such as circulating tumour DNA (ctDNA) analysis has the advantage of monitoring response to treatment in real time and providing a comprehensive genotypic profile of primary, metastatic, and recurrent tumours. Thus, ctDNA analysis can be used as a complementary test for effective diagnosis and monitoring of OC. We comprehensively review current studies (2019–2024) on OC, critically highlighting recent developments and applications of ctDNA for the diagnosis and management of the disease.
